Dynamics of Anti-S IgG Antibodies Titers after the Second Dose of COVID-19 Vaccines in the Manual and Craft Worker Population of Qatar
Author | Bansal, Devendra |
Author | Atia, Hassan |
Author | Al Badr, Mashael |
Author | Nour, Mohamed |
Author | Abdulmajeed, Jazeel |
Author | Hasan, Amal |
Author | Al-Hajri, Noora |
Author | Ahmed, Lina |
Author | Ibrahim, Rumissa |
Author | Zamel, Reham |
Author | Mohamed, Almuthana |
Author | Pattalaparambil, Hamad |
Author | Daraan, Faisal |
Author | Chaudhry, Adil |
Author | Oraby, Sahar |
Author | El-Saleh, Sahar |
Author | El-Shafie, Sittana S. |
Author | Al-Farsi, Affra Faiz |
Author | Paul, Jiji |
Author | Ismail, Ahmed |
Author | Al-Romaihi, Hamad Eid |
Author | Al-Thani, Mohammed Hamad |
Author | Doi, Suhail A.R. |
Author | Zughaier, Susu M. |
Author | Cyprian, Farhan |
Author | Farag, Elmobashar |
Author | Farooqui, Habib Hasan |
Available date | 2023-05-03T09:52:23Z |
Publication Date | 2023-02-21 |
Publication Name | Vaccines |
Identifier | http://dx.doi.org/10.3390/vaccines11030496 |
Citation | Bansal, D., Atia, H., Al Badr, M., Nour, M., Abdulmajeed, J., Hasan, A., ... & Farooqui, H. H. (2023). Dynamics of Anti-S IgG Antibodies Titers after the Second Dose of COVID-19 Vaccines in the Manual and Craft Worker Population of Qatar. Vaccines, 11(3), 496. |
ISSN | 2076-393X |
Abstract | There is limited seroepidemiological evidence on the magnitude and long-term durability of antibody titers of mRNA and non-mRNA vaccines in the Qatari population. This study was conducted to generate evidence on long-term anti-S IgG antibody titers and their dynamics in individuals who have completed a primary COVID-19 vaccination schedule. A total of 300 male participants who received any of the following vaccines BNT162b2/Comirnaty, mRNA-1273, ChAdOx1-S/Covishield, COVID-19 Vaccine Janssen/Johnson, or BBIBP-CorV or Covaxin were enrolled in our study. All sera samples were tested by chemiluminescent microparticle immunoassay (CMIA) for the quantitative determination of IgG antibodies to SARS-CoV-2, receptor-binding domain (RBD) of the S1 subunit of the spike protein of SARS-CoV-2. Antibodies against SARS-CoV-2 nucleocapsid (SARS-CoV-2 N-protein IgG) were also determined. Kaplan–Meier survival curves were used to compare the time from the last dose of the primary vaccination schedule to the time by which anti-S IgG antibody titers fell into the lowest quartile (range of values collected) for the mRNA and non-mRNA vaccines. Participants vaccinated with mRNA vaccines had higher median anti-S IgG antibody titers. Participants vaccinated with the mRNA-1273 vaccine had the highest median anti-S-antibody level of 13,720.9 AU/mL (IQR 6426.5 to 30,185.6 AU/mL) followed by BNT162b2 (median, 7570.9 AU/mL; IQR, 3757.9 to 16,577.4 AU/mL); while the median anti-S antibody titer for non-mRNA vaccinated participants was 3759.7 AU/mL (IQR, 2059.7–5693.5 AU/mL). The median time to reach the lowest quartile was 3.53 months (IQR, 2.2–4.5 months) and 7.63 months (IQR, 6.3–8.4 months) for the non-mRNA vaccine recipients and Pfizer vaccine recipients, respectively. However, more than 50% of the Moderna vaccine recipients did not reach the lowest quartile by the end of the follow-up period. This evidence on anti-S IgG antibody titers should be considered for informing decisions on the durability of the neutralizing activity and thus protection against infection after the full course of primary vaccination in individuals receiving different type (mRNA verus non-mRNA) vaccines and those with natural infection. |
Sponsor | The World Health Organization (WHO) - grant number [2021/1183356-0]. |
Language | en |
Publisher | Multidisciplinary Digital Publishing Institute (MDPI) |
Subject | anti-S IgG antibody titer COVID-19 mRNA vaccines non-mRNA vaccines |
Type | Article |
Issue Number | 3 |
Volume Number | 11 |
ESSN | 2076-393X |
Files in this item
This item appears in the following Collection(s)
-
COVID-19 Research [798 items ]
-
Medicine Research [1379 items ]